Safety
In the eltrombopag group, there were no cases of eltrombopag withdrawal due to adverse reactions. The most common adverse events were indirect bilirubin elevation and jaundice (13.6%, 9 patients). Three patients (4.5%) showed transient elevations of liver enzyme levels. One patient showed elevated uric acid (1.5%). The above abnormal laboratory indicators self-resolved or disappeared after eltrombopag withdrawal. None of the patients developed new cataracts or thromboembolic events during the study, and no rashes or myelofibrosis were reported. Adverse events not attributed to eltrombopag by the investigators included neutropenic infections and known toxic effects of rATG and CSA. One patient showed femoral head necrosis at 1 year after IST, which improved after surgery.